licensing

News

AstraZeneca builds in cancer ADCs again, with LaNova deal

AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base

News

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil

News

Sanofi finds new Pompe disease therapy in Maze

Sanofi is already a big player in the Pompe disease market with injectable drugs like Nexviazyme and Myozyme/Lumizyme, but has now set its sights on an oral drug candidate

News

GSK told to pay higher royalties to AZ on Zejula sales

A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito

News

Merck sets sights on Epstein-Barr virus jab with Opko deal

Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.

News

Takeda grabs ex-China fruquintinib rights from Hutchmed

Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of

AstraZeneca builds in cancer ADCs again, with LaNova deal

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Sanofi finds new Pompe disease therapy in Maze

GSK told to pay higher royalties to AZ on Zejula sales

Merck sets sights on Epstein-Barr virus jab with Opko deal

Takeda grabs ex-China fruquintinib rights from Hutchmed

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

licensing

Editor's Picks